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Abstract
Background—Sarcopenia is defined as the loss of muscle mass or function with aging and is 
associated with adverse outcomes. Telomere shortening is associated with mortality, yet its 
relationship with sarcopenia is unknown.
Methods—Adults ≥60 years from the 1999–2002 NHANES with body composition measures 
were identified. Sarcopenia was defined using the two Foundation for the National Institute of 
Health definitions: appendicular lean mass (ALM) (men<19.75; women<15.02kg); or ALM 
divided by body mass index (BMI) (ALM:BMI, men<0.789; women<0.512). Telomere length was 
assessed using quantitative PCR. Regression models predicted telomere length with sarcopenia 
(referent=no sarcopenia).
Results—We identified 2,672 subjects. Mean age was 70.9 years (55.5% female). Prevalence of 
ALM and ALM:BMI sarcopenia was 29.2 and 22.1%. Deaths were higher in persons with 
sarcopenia as compared to those without sarcopenia (ALM: 46.4 vs. 33.4%; p<0.001; ALM:BMI: 
46.7 vs.33.2%; p<0.001). No adjusted differences were observed in telomere length in those with/
without sarcopenia (ALM: 0.90 vs. 0.92; p=0.74, ALM:BMI 0.89 vs. 0.92; p=0.24). In men with 
ALM:BMI defined sarcopenia, adjusted telomere length was significantly lower compared to men 
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without sarcopenia (0.85 vs 0.91, p=0.013). With sarcopenia, we did not observe a significant 
association between telomere length and mortality (ALM: HR 1.11 [0.64, 1.82], p=0.68; 
ALM:BMI: HR 0.97 [0.53,1.77], p=0.91), but noted significance in those without sarcopenia with 
mortality (ALM: HR 0.59 [0.40, 0.86], p=0.007; ALM:BMI: HR 0.62 [0.42, 0.91]; p=0.01).
Conclusions—We observed a potentially inverse relationship between telomere length and 
mortality in those without sarcopenia but did not observe a significant relationship between 
telomere length and mortality in the presence of sarcopenia.
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sarcopenia; telomere; mortality; epidemiology; aging
Introduction
Sarcopenia has been defined as the loss of muscle mass and/or strength with aging1. The 
aging process can be affected by many epigenetic factors including smoking, air pollution, 
and diet2–4. Partly due to the impaired muscle enzymatic system that degrades reactive 
oxygen species, there is an increased exposure to these toxic entities that develops with 
aging that may hasten the development of sarcopenia5. This results in reduced redox 
regulation and leads to further increases in reactive oxygen species6 both of which can lead 
to senescence5.
Increased oxidative stress in the absence of preserved protective mechanisms can damage 
DNA, including telomere segments7. Telomeres are lengths of non-transcriptional DNA 
which serve to protect DNA from degradation8, and their shortening is strongly associated 
with the aging process9. Smoking and exposure to air pollution are both known to cause 
oxidative stress and resultant shortening of telomeres, which in turn can have a significant 
negative impact on health3, 10. Individuals with shorter telomeres have a higher risk of 
developing cardiovascular disease11, reduced angiogenic potential12, and are at an increased 
risk of mortality13.
Both sarcopenia and decreased telomere length are affected by oxidative stress and are each 
related to mortality5, 8. Yet, the relationship between these two entities is unknown. The 
purpose of this study was to evaluate the relationship between telomere length, sarcopenia, 
and mortality. The recently proposed sarcopenia definitions by the Foundation for the 
National Institutes of Health (FNIH)14 were applied in this study to assist with the 
classification of individuals at risk for functional decline. We hypothesized that: 1) the 
presence of muscle mass defined sarcopenia among adults aged 60 and older is associated 
with decreased telomere length; and 2) that all-cause mortality will be directly associated 
with decreased telomere length and sarcopenia.
METHODS
Survey & Study Cohort
The National Health and Nutrition Examination Survey 1999–2002 (NHANES) is a cross-
sectional survey that is representative of non-institutionalized, community-dwelling adults. 
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This study performed a secondary analysis of data from this specific survey. The Centers for 
Disease Control and Prevention has conducted this survey since 1971, and its content can be 
found at https://www.cdc.gov/nchs/nhanes/index.htm (accessed July 2016). The use of de-
identified data exempted this study from review by the local institutional review board.
There were a total of 25,316 participants screened, of which 21,004 were interviewed and 
19,759 were examined in a standardized mobile examination center. Individuals without 
telomere data or body composition data were excluded from the final analytic sample 
(n=8,044). As the prevalence of sarcopenia is higher in adults aged 60 and over15, we 
restricted our analysis to this age group. Our final analytical cohort consisted of 2,672 
subjects.
Body Composition Measures
Duel energy x-ray absorptiometry (DEXA), using a QDR-4500 Hologic Scanner (Bedford, 
MA), assessed body composition (muscle mass and body fat). This assessment excluded 
individuals with a height of >192.5 cm or a weight of >136.4 kg. All metal, excluding false 
teeth and hearing aids, was removed prior to assessment. Appendicular lean mass (ALM) 
was defined as the combined fat-free mass for all four extremities (arms and legs). We used 
the FNIH criteria for ALM-defined sarcopenia (<19.75kg in males, <15.02kg in females) 
and ALM adjusted for body mass index (BMI) (<0.789 kg for males, <0.512 kg for 
females). For this study, we defined obesity in males as a body fat percentage >25%, and for 
female >35%, as defined in our previous studies16.
Telomere Data
Blood samples were obtained from participants, and the assay was performed at the 
University of California, San Francisco using quantitative polymerase chain reaction to 
compare the telomere length of the subjects relative to a standard reference DNA (T/S 
ratio)17, 18. Each sample was duplicated and assayed 3 times on 3 different days. Each assay 
plate contained 96 control wells with 8 control DNA samples. Assay runs with 8 or more 
invalid control wells, or those runs with more than 4 control DNA values falling outside 2.5 
standard deviations from the mean for all assay runs were excluded from further analysis 
(<1% and <6% of runs, respectively). Potential outliers were also identified and excluded 
(<2% of samples). Control DNA values were used to normalize between-run variability. The 
mean and standard deviation of the T/S ratio were calculated. Interassay coefficient of 
variation was 6.5%. Quality control assurance and monitoring was regularly performed.
Baseline Characteristics
A self-report questionnaire assessed race, medical comorbidities, smoking status, and 
physical activity. All races were included (non-Hispanic White, non-Hispanic Black, 
Hispanic, and other). Smoking status was classified as never smoker, former smoker, and 
current smoker of cigarettes. Physical activity level was classified according to the degree of 
strenuousness (sitting, walking, light loads, and heavy loads). Anthropometric measurements 
were estimated to the nearest tenth of a centimeter on the right side of the body, except 
where amputations, casts, and other factors impeded such measurements. Weight was 
determined with an electronic digital scale (kilograms), and height (meters) was determined 
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by a stadiometer after deep inhalation. Body Mass Index (BMI) was calculated as weight 
(kilograms) divided by height squared (meters squared). Waist Circumference (WC) was 
measured standing at the height of the iliac crest by wrapping a tape around the trunk, 
making sure that it crossed the mid-axillary line at right angles.
Mortality Analysis
Data was obtained through the NHANES 1999–2002 survey which used a probabilistic 
match to a National Death Index, as well as information from the Social Security 
Administration to determine mortality status. Mortality data was complete up to December 
31st, 2011. Cause of death was classified as cardiovascular (including stroke) or other, 
following the International Statistical Classification of Disease, Injuries and Causes of Death 
guidelines with the 9th revision used for those dying in 1999, and the 10th revision for all 
others. Procedures are in place to harmonize the differences in definitions and causes of 
death. Time of follow-up was calculated in months from interview date, to date of death or 
most recent vital record. Vital status was accounted for in >99% of our sample.
Statistical Analysis
All data was merged into a single dataset for analysis. Weighting using NHANES analytical 
procedures to account for the complex, stratified sampling was performed for all analyses. 
Continuous variables are represented as means ± standard errors, and categorical variables as 
counts (weighted percentages). T-tests compared means and chi-squares for categorical 
values, or their non-parametric equivalents assessed differences among baseline 
characteristics. Data are presented as the overall cohort age ≥60 years, by age group (60–
69.9, 70–79.9, and ≥80 years), and by the presence/absence of sarcopenia based on the ALM 
and ALM:BMI definitions. Differences among age groups were tested by ANOVA. The 
primary goal was: a) to present the adjusted mean telomere length in those with/without 
muscle mass defined sarcopenia; b) assess the association of telomere length (independent 
variable) with mortality in those with and without sarcopenia. Three separate linear 
regression models were created: model 1 was unadjusted; model 2 adjusted for age, sex, 
race, education and smoking status; model 3 additionally adjusted for diabetes, congestive 
heart failure, non-skin cancer, coronary artery disease, and physical activity. Sex-specific 
modeling was also performed to ascertain mean adjusted telomere length. Separate Cox 
proportional hazard models were created to ascertain the risk of death with and without 
sarcopenia associated with telomere length. We further added a sarcopenia × telomere 
interaction in each model. Hazard ratios [95% confidence intervals] are presented. All 
analyses were performed with STATA version 13 (College Station, TX). A p-value <0.05 
was considered statistically significant.
RESULTS
Baseline characteristics are presented in Table 1. Of the 2,672 participants, the mean age 
was 70.9±0.28 (49.1% females). The prevalence of ALM and ALM:BMI defined sarcopenia 
was 14.6 and 27.0%, in males, and 40.7% and 18.1%, in females, respectively. Patterns of 
clinical comorbidities, such as diabetes mellitus, congestive heart failure, and coronary 
artery disease vary based on the definition of sarcopenia. Table 2 displays the unadjusted 
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mean telomere length and death rates by sarcopenia definition. Telomere length decreased 
with age. The unadjusted telomere length in the over 60 age group was different in those 
with sarcopenia compared to those without sarcopenia (ALM: 0.90±0.02 vs. 0.92±0.02; 
p=0.09; ALM:BMI: 0.88±0.02 vs. 0.92±0.02; p=0.004). Examining the pre-specified age 
categories, the ≥80 year age group significantly demonstrated a difference between telomere 
length by sarcopenia status (ALM: 0.82±0.02 vs.0.86±0.02; p=0.02; ALM:BMI: 0.81±0.02 
vs. 0.86±0.02; p=0.02). Overall mortality rates were higher with sarcopenia compared to 
without (ALM: 46.4 vs. 33.4%, p<0.001; ALM:BMI: 46.7 vs. 33.2%, p<0.001), as was 
cardiovascular mortality (ALM: 12.6 vs 7.7%; p=0.012; ALM:BMI: 14.0 vs 7.1%; p=0.008).
After adjusting for covariates (Table 3) no significant overall association was observed 
between telomere length and the presence of sarcopenia (ALM: 0.90 vs. 0.92, p=0.74; 
ALM:BMI 0.89 vs. 0.92, p=0.24). However, we observed sex-specific differences in the 
adjusted association of telomere length and sarcopenia. Adjusted telomere length was 
shorter in men (0.89±0.02 vs. 0.93±0.02; p<0.001). In men, a significant difference in 
telomere length was observed when the ALM:BMI definition of sarcopenia was applied and 
mean lengths were adjusted for age, race, education (Model 2: 0.85±0.02 vs 0.90±0.02; 
p=0.004). This difference remained between men with or without sarcopenia when means 
were adjusted for diabetes, congestive heart failure, non-skin cancer, coronary artery disease, 
arthritis, physical activity, and smoking status (Model 3: 0.85±0.02 vs 0.91±0.02; p=0.013). 
Further adjustment for CRP did not alter these differences (data not shown).
Table 4 highlights the univariate and multivariable models for the association of sarcopenia 
and telomere length with mortality. In the absence of sarcopenia, telomere length was 
significantly associated with overall mortality (ALM: HR 0.59 [0.40, 0.86]; ALM:BMI: HR 
0.62 [0.42,0.91]. The presence of sarcopenia did not contribute to any significant differences 
in risk of death (ALM: HR 1.11 [0.64, 1.82]; ALM:BMI: HR 0.97 [0.53,1.77]). Importantly, 
an interaction was observed between sarcopenia and telomere length using both definitions 
of sarcopenia (p=0.03 and p=0.04, respectively) for overall mortality. We did not observe an 
association between telomere length and cardiovascular mortality.
DISCUSSION
The study results confirm the known inverse relationship between age and telomere length 
but despite our previously reported association between sarcopenia and mortality16, we did 
not observe a significant relationship between telomere length and mortality. We also 
observed differences in telomere length by overall sarcopenia status in men only. Finally, 
increased telomere length, in the presence of sarcopenia, was not associated with reduced 
risk of mortality.
Telomere length was no different by overall sarcopenia status both univariately and 
multivariately in older adults. These results support those by Woo19 and Mather20 and differ 
slightly than the weak association observed in the Berlin Aging Study II21 or by the results 
from Marzetti22 who used the European Working Group on the Study of Sarcopenia23. We 
were surprised as sarcopenia has been shown to lead to shorter lifespans23. Aging also leads 
to both the development of sarcopenia and to telomere shortening. These findings provide an 
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important understanding as to the underlying biology. While aging24, 25, telomere length26 
and sarcopenia27 are all associated with pro-inflammatory cytokines, the lack of a causal 
relationship, perhaps due to the cross-sectional nature of the data, suggests that the impact of 
inflammation and/or differences in length may have occurred later in life. Using both the 
ALM and ALM:BMI definitions, we observed significantly higher telomere lengths in 
individuals without sarcopenia in the age ≥80 years, as compared to those with sarcopenia. 
These results may indicate a survivor effect of the very old that has been observed in other 
studies28. NHANES oversamples this age group as it is under-represented, and as such, 
future analyses should focus on this particular age demographic.
Importantly, we observed sex-specific differences in the relationship between telomere 
length and sarcopenia using the ALM:BMI definition of sarcopenia. Males with sarcopenia 
had lower telomere lengths than those without in all models. Estrogen has been shown to 
protect telomeres from oxidative stress29 as evidenced by the longer telomere segments in 
females than in males. Previous studies have demonstrated conflicting results between sexes 
among the association of functional impairments, inflammation and mortality with muscle 
mass16, 30. In fact, this may partly be due to the adjustment of BMI which preferentially has 
different diagnostic accuracy for adiposity in males than in females31. This could also be due 
to differences in body composition between sexes and the distribution of adipose tissue32. 
Future research is needed to better understand the sex-specific changes that impact muscle 
biology.
The absence of sarcopenia suggests an improvement in overall mortality with higher 
telomere length. Epidemiologically, this is consistent with the inverse relationship between 
telomere length and death. Our study complements the literature evaluating telomere length 
and mortality, and expands the analysis to include sarcopenia. We deliberately used the 
standardized FNIH definitions to assess the telomere/sarcopenia relationship and found a 
weak interaction in our mortality models suggesting that sarcopenia modified the 
relationship between telomere length and mortality. One possible hypothesis is due to the 
impact of increased inflammation on telomere length. Muscles release myokines with each 
contraction, which serve a protective role33 against chronic diseases associated with low-
grade inflammation34. We speculated that the decreased muscle mass among those with 
sarcopenia would contribute to fewer anti-inflammatory mediators being released following 
contractions, and thus expose muscles to a more pro-inflammatory environment. This would 
cause myocyte apoptosis and atrophy8.
There was no statistically significant relationship observed between cardiovascular mortality 
and telomere length in those with and without sarcopenia. A number of potential reasons 
could explain these results. First, we were reliant on cause of death from death certificates. 
Second, the number of deaths in each category was rather low. Third, our results confirm 
those by Rode et al who demonstrated a lack of a relationship between telomere length and 
cardiovascular mortality35. Recently, some authors have proposed a robust hypothesis that 
telomere length is inversely associated with atherosclerosis and its outcomes. This paradigm 
was based on an accelerated rate of telomere length attrition due to heightened oxidative 
stress and inflammation. In a more pro-inflammatory environment, telomeres experience 
more rapid shortening8. The number of inflammatory mediators assessed in NHANES are 
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minimal and do not include important cytokines (IL-1, IL-6, TNF-a). Even after adjusting 
for C-reactive protein, our results were no different (data not shown). We could not ascertain 
the progression of telomere length shortening for each participant throughout their lifetime, 
nor could we ascertain the extent of inflammation or change in telomere length each 
participant experienced. Testing and evaluating these theories in this population requires not 
only larger sample sizes but markers of inflammation beyond C-reactive protein.
NHANES collects and analyzes telomere length in a highly standardized manner which 
allows for more consistent comparisons across the study populations. Telomere assays were 
performed at the University of California, a distant site to laboratory collection and 
processing. The integrity of the analysis and the long-term degradation of the samples are 
dependent on multiple factors, including storage, DNA extraction, processing, transportation 
and de-thawing. This may ultimately impact the results observed. Importantly, the ability to 
relate clinical measures to biological biomarkers is a unique strength of NHANES. Yet, the 
cross-sectional nature of the study does not allow for the determination of causality. This 
iteration of NHANES does not contain data on muscle strength which has better predictive 
validity in ascertaining long-term outcomes than muscle mass. Muscle strength has been 
shown to be a better mortality predictor in older adults36. Additionally, while the analysis 
accounted for the complex, stratified, sampling, the results cannot be extrapolated to a non-
institutionalized population who may be at higher risk for developing sarcopenia than 
community-dwelling persons. While the mean age of the sample is within the range 
observed in the FNIH validation cohorts, it nonetheless suggests that this cohort may not 
approximate populations at highest risk. Lastly, we acknowledge that this survey lends itself 
to self-report bias.
Implications
This research has a number of important potential clinical implications for future studies. 
Our results provide preliminary evidence that while reduced telomere length may predict 
mortality in older adults, telomere length in individuals with sarcopenia, due to complexities 
of adiposity associated with sarcopenia, may have less predictive validity and may not be as 
useful of a biomarker as originally believed. Telomeres could potentially be used in healthier 
populations to predict longer term outcomes, earlier in the disablement process. Future 
research should evaluate the relationship between telomere length in individuals with 
sarcopenia defined using a measure of muscle strength (ie: grip strength) to confirm/refute 
this relationship. Telomere lengths are dependent on lifelong physical activity. Even though 
we adjusted for self-reported physical activity, without having a firm understanding of a life-
course approach to such suggests that it may act as a confounding factor, as a sedentary 
lifestyle increases the risk of death. Future studies should evaluate such longitudinal 
approaches but also further evaluate inflammatory conditions of older adults, such as 
osteoarthritis, rheumatoid arthritis, chronic low grade infections, and dementia, and evaluate 
these diseases in relation to telomere length and sarcopenia.
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CONCLUSIONS
In the presence of sarcopenia, decreased telomere length had no potentially significant effect 
on predicted mortality in adults age 60 and older.
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